Orthofix Medical Reports Q1 2025 Financial Growth

Orthofix International ( (OFIX) ) has released its Q1 earnings. Here is a breakdown of the information Orthofix International presented to its investors.

Orthofix Medical Inc., a global leader in medical technology, specializes in spinal hardware, bone growth therapies, and orthopedic solutions. The company recently released its financial results for the first quarter of 2025, showcasing growth in several key areas despite reporting a net loss.

In the first quarter of 2025, Orthofix reported net sales of $193.6 million, marking a 2.7% increase from the previous year. Excluding the discontinued M6 artificial disc product lines, pro forma net sales grew by 4.3%. The company achieved a non-GAAP pro forma adjusted EBITDA of $11.4 million, reflecting a 49.1% growth over the prior year. Notable achievements include the 510(k) clearance and CE Mark for the TrueLok™ Elevate Transverse Bone Transport System.

Orthofix’s Bone Growth Therapies saw a 5% increase in net sales, while Global Orthopedics achieved an 11% growth in constant currency terms. However, the company reported a net loss of $53.1 million, attributed to strategic optimization efforts in its commercial channels, which are expected to enhance future growth.

Looking forward, Orthofix has updated its full-year net sales guidance to range between $808 million and $816 million, maintaining its adjusted EBITDA and free cash flow guidance. The company remains focused on improving gross margins, expanding market share, and ensuring disciplined capital allocation to create long-term shareholder value.